Payer Quality Improvement Programs with Freespira
The company that developed Freespira, Palo Alto Health Sciences, is partnering with several large commercial payers, including Anthem and Highmark to confirm the expected cost savings in patients with panic following treatment with Freespira. These programs seek to demonstrate that the clinical improvements seen following treatment by Freespira directly translate into lower healthcare utilization and lower system costs based on the hypothesis that once PD patients no longer experience panic attacks and symptoms of panic, their utilization of medical care will be similar to that of a matched control group (i.e. members who do not have claims for panic disorder).
To learn more about these programs, or to find out how Freespira can help lower costs for your organization, contact us today.